Multifunctional gadolinium oxide nanoparticles: Towards image-guided therapy

Imaging in Medicine

Volumn 2, Issue 2, 2010, Pages 211-223

  Roux, Stéphane ^b   Faure, Anne Charlotte ^b   Mandon, Céline ^b   Dufort, Sandrine ^b   Rivire, Charlotte ^b   Bridot, Jean Luc ^b   Mutelet, Brice ^b   Marquette, Christophe A ^b   Josserand, Véronique ^b   Le Duc, Géraldine ^b   Le Pape, Alain ^b   Billotey, Claire ^b   Janier, Marc ^b   Coll, Jean Luc ^b   Perriat, Pascal ^b   Tillement, Olivier ^a  

^a UNIVERSITÉ LYON 1   (France)

^b NONE

Author keywords

biomolecule detection; fluorescence imaging; gadolinium oxide; MRI; nanoparticle; neutron capture; radiotherapy

Indexed keywords

GADOLINIUM OXIDE; GADOLINIUM PENTETATE ALBUMIN; NANOPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; POLYSILOXANE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOLUMINESCENCE; BIOSENSOR; CANCER THERAPY; CONTRAST ENHANCEMENT; FLUORESCENCE IMAGING; HUMAN; NANOMEDICINE; NANOPROBE; NANOTECHNOLOGY; NEUTRON RADIATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTON; PRIORITY JOURNAL; REVIEW; SYNTHESIS;

EID: 77954094328     PISSN: 17555191     EISSN: 17555205     Source Type: Journal    
DOI: 10.2217/iim.10.5     Document Type: Review

References (81)

1. Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5, 161-171 (2005).
2. Piao Y, Burns A, Kim J, Wiesner U, Hyeon T: Designed fabrication of silica-based nanostructured particles systems for nanomedicine applications. Adv. Funct. Mater. 18, 1-14 (2008).
3. Riehemann K, Schneider SW, Luger TA, Godin B, Ferrari M, Fuchs H: Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. 48, 872-897 (2009).
4. Sarin H: Recent progress towards the development of effective systemic chemotherapy for the treatment of malignant brain tumors. J. Translational Med. 7, 77 (2009).
5. Yong KT, Roy I, Swihart MT, Prasad PN: Multifunctional nanoparticles as biocompatible targeted probes for human cancer diagnosis and therapy. J. Mater. Chem. 19, 4655-4672 (2009).
6. Kim J, Piao Y, Hyeon T: Multifunctional nanostructured materials for multimodal imaging, and simultaneous imaging and therapy. Chem. Soc. Rev. 38, 372-390 (2009).
7. Gao JH, Gu HW, Xu B: Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc. Chem. Res. 42, 1097-1107 (2009).
8. Boisselier E, Astruc D: Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity Chem. Soc. Rev. 38, 1759-1782 (2009).
9. Sharma R, Chen CJ: Newer nanoparticles in hyperthermia treatment and thermometry. J. Nanopart. Res. 11, 671-689 (2009).
10. Dennis CL, Jackson AJ, Borchers JA et al.: Nearly complete regression of tumors via collective behavior of magnetic nanoparticles in hyperthermia. Nanotechnology 20, 395103 (2009).
11. Thomas LA, Dekker L, Kallumadil M et al.: Carboxylic acid-stabilised iron oxide nanoparticles for use in magnetic hyperthermia. J. Mater. Chem. 19, 6529-6535 (2009).
12. Laurent S, Forge D, Port M et al.: Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications. Chem. Rev. 108, 2064-2110 (2008).
13. Hainfeld JF, Slatkin DN, Focella M, Smilowitz HM: Gold nanoparticles: a new X-ray contrast agents. Brit. J. Radiol. 79, 248-253 (2006).
14. Popovtzer R, Agrawal A, Kotov NA et al.: Targeted gold nanoparticles enable molecular CT imaging of cancer. Nano Lett. 8, 4593-4596 (2008).
15. Hainfeld JF, Slatkin DN, Smilowitz HM: The use of gold nanoparticles to enhance radiotherapy in mice. Phys. Med. Biol. 49, N309-N315 (2004).
16. Alric C, Serduc R, Mandon C et al.: Gold nanoparticles designed for combining dual modality imaging and radiotherapy Gold Bull. 41, 90-97 (2008).
17. Loo C, Lowery A, Halas N, West J, Drezek R: Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett. 5, 709-711 (2005).
18. Huang X, El-Sayed IH, Qian W, El-Sayed M: Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J. Am. Chem. Soc. 128, 2115-2120 (2006).
19. Gobin AM, Lee MH, Halas NJ, James WD, Drezek RA, West JL: Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy. Nano Lett. 7, 1929-1934 (2007).
20. Chen J, Wang D, Xi J et al.: Immuno gold nanocages with tailored optical properties for targeted photothermal destruction of cancer cells. Nano Lett. 7, 1318-1322 (2007).
21. Debouttière PJ, Roux S, Vocanson F et al.: Design of gold nanoparticles for magnetic resonance imaging. Adv. Funct. Mater. 16, 2330-2339 (2006).
22. Alric C, Taleb J, Le Duc G et al.: Gadolinium chelate coated gold nanoparticles as contrast agents for both X-ray computed tomography and magnetic resonance imaging. J. Am. Chem. Soc. 130, 5908-5915 (2008).
23. Caravan P, Ellison JJ, McMury TJ, Lauffer RB: Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 99, 2293-2352 (1999).
24. Bottrill M, Kwok L, Long NJ: Lanthanides in magnetic resonance imaging. Chem. Soc. Rev. 35, 557-571 (2006).
25. Soloway AH, Tjarks W, Barnum BA et al.: The chemistry of neutron capture therapy. Chem. Rev. 98, 1515-1562 (1998).
26. Garber K: Neutron Cross Sections Report A, BNI-325 (3rd Edition). Brookhaven National Laboratory, NY, USA (1976).
27. Shi JL, Brugger RM: Gadolinium as a neutron capture therapy agent. Med. Phys. 19, 733-744 (1992).
28. Hofmann B, Fischer CO, Lawaczeck R et al.: Gadolinium neutron capture therapy (GdNCT) of melanoma cells and solid tumors with the magnetic resonance imaging contrast agent gadobutrol. Invest. Radiol. 34, 126-133 (1999).
29. De Stasio C, Casalbore P, Pallini R et al.: Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res. 61, 4272-4277 (2001).
30. Li SD, Huang L: Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharmaceutics 5, 496-504 (2008).
31. Wiener EC, Auteri FP, Chen JW et al.: Molecular dynamics of ion-chelate complexes attached to dendrimers. J. Am. Chem. Soc. 118, 7774-7782 (1996).
32. Daldrup-Link HE, Brasch RC: Macromolecular contrast agents for MR mammography: current status. Eur. Radiol. 13, 354-365 (2003).
33. Farokhzad OC, Langer R: Impact of nanotechnology in drug delivery. ACS Nano 3, 16-20 (2009).
34. Huber MM, Staubli AB, Kustedjo K et al.: Fluorescently detectable magnetic resonance imaging agents. Bioconjug. Chem. 9, 242-249 (1998).
35. Yan GP, Liu ML, Li LY: Polyaspartamide gadolinium complexes containing sulfadiazine groups as potential macromolecular MRI contrast agents. Bioconjug Chem. 16, 967-971 (2005).
36. Bull SR, Guler MO, Bras RE, Venkatasubramanian PN, Stupp SI, Meade TJ: Magnetic resonance imaging of self-assembled biomaterial scaffolds. Bioconjug. Chem. 16, 1343-1348 (2005).
37. Bull SR, Guler MO, Bras RE, Meade TJ, Stupp SI: Self-assembled peptide amphiphile nanofbers conjugated to MRI contrast agents. Nano Lett. 5, 1-4 (2005).
38. Anderson EA, Isaacman S, Peabody DS, Wang EY, Canary J W, Kirshenbaum K: Viral nanoparticles donning a paramagnetic coat: conjugation of MRI contrast agents to the MS2 capsid. Nano Lett. 6, 1160-1164 (2006).
39. Langereis S, de Lussanet QG, van Genderen MHP, Backes WH, Meijer EW: Multivalent contrast agents based on gadolinium-diethylenetriaminepentaacetic acid-terminated poly(propylene imine) dendrimers for magnetic resonance imaging. Macromolecules 37, 3084-3091 (2004).
40. Talanov VS, Regino CA, Kobayashi H, Bernardo M, Choyke PL, Brechbiel MW: Dendrimer-based nanoprobe for dual modality magnetic resonance and fuorescence imaging. Nano Lett. 6, 1459-1463 (2006).
41. Mulder WJM, Strijkers GJ, Griffoen AW et al.: A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug. Chem. 15, 799-806 (2004).
42. Accardo A, Tesauro D, Roscigno P et al.: Physicochemical properties of mixed micellar aggregates containing CCK peptides and Gd complexes designed as tumor specifc contrast agents in MRI. J. Am. Chem. Soc. 126, 3097-3107 (2004).
43. Parac-Vogt TN, Kimpe K, Laurent S et al.: Gadolinium DTPA-monoamide complexes incorporated into mixed micelles as possible MRI contrast agents. Eur. J. Inorg. Chem. 17, 3538-3543 (2004).
44. Reynolds CH, Annan N, Beshah K et al.: Gadolinium-loaded nanoparticles: new contrast agents for magnetic resonance imaging. J. Am. Chem. Soc. 122, 8940-8945 (2000).
45. Turner JL, Pan D, Plummer R, Chen Z, Whittaker AK, Wooley KL: Synthesis of gadolinium-labeled shell-crosslinked nanoparticles for magnetic resonance imaging applications. Adv. Funct. Mater. 15, 1248-1254 (2005).
46. Toth E, Bolskar RD, Borel A et al.: Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J. Am. Chem. Soc. 127, 799-805 (2005).
47. Sitharaman B, Kissell KR, Hartman KB et al.: Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem. Commun. 3915-3917 (2005).
48. Balkus KJ, Shi J: A study of suspending agents for gadolinium(III)- exchanged hectorite-an oral magnetic resonance imaging contrast agent. Langmuir 12, 6277-6281 (1996).
49. Lin YS, Hung Y, Su JK et al.: Gadolinium(III)-incorporated nanosized mesoporous silica as potential magnetic resonance imaging contrast agents. J. Phys. Chem. B 108, 15608-15611 (2004).
50. Frias JC, Williams KJ, Fisher EA, Fayad ZA: Recombinant HDL-like nanoparticles: a specifc contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126, 16316-16317 (2004).
51. Frias JC, Ma Y, Williams KJ, Fayad ZA, Fisher EA: Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 6, 2220-2224 (2006).
52. Mulder WJ, Koole R, Brandwijk RJ et al.: Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett. 6, 1-6 (2006).
53. van Tilborg GA, Mulder WJ, Chin PT et al.: Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug. Chem. 17, 865-868 (2006).
54. Vuu K, Xie J, McDonald MA et al.: Gadolinium-rhodamine nanoparticles for cell labeling and tracking via magnetic resonance and optical imaging. Bioconjug. Chem. 16, 995-999 (2005).
55. 1 relaxivity of core-encapsulated gadolinium liposomal contrast agents-effect of liposome size and internal gadolinium concentration. Acad. Radiol. 15, 1259-1263 (2008).
56. Roberts D, Zhu WL, Frommen CM, Rosenzweig Z: Synthesis of gadolinium oxide magnetoliposomes for magnetic resonance imaging. J. Appl. Phys. 87, 6208-6210 (2000).
57. Engström M, Klasson A, Pedersen H, Vahlberg C, Käll PO, Uvdal K: High proton relaxivity for gadolinium oxide nanoparticles. Magn. Reson. Mater. Phy. 19, 180-186 (2006).
58. McDonald MA, Watkin KL: Small particulate gadolinium oxide and gadolinium oxide albumin microspheres as multimodal contrast and therapeutic agents. Invest. Radiol. 38, 305-310 (2003).
59. 3 nanoparticles: physical characterization and NMR relaxation properties. Chem. Mater. 18, 2499-2505 (2006).
60. 4 nanocrystals. Adv. Funct. Mater. 19, 853-859 (2009).
61. Li IF, Su CH, Sheu HS et al.: Synthesis and applications of magnetic resonance contrast agents. Adv. Funct. Mater. 18, 766-776 (2008).
62. 2O/silica/gold hybrid particles as a bifunctional agent for MR imaging and photothermal destruction of cancer cells. J. Mater. Chem. 19, 2147-2153 (2009).
63. Prezado Y, Fois G, Le Duc G, Bravin A: Gadolinium dose enhancement studies in microbeam radiation therapy. Med. Phys. 36, 3568-3574 (2009).
64. 3. Eur. J. Colloid Interface Sci. 273, 191-197 (2004).
65. Bazzi R, Flores-Gonzalez MA, Louis C et al.: Synthesis and luminescent properties of sub-5-nm lanthanide oxides nanoparticles. J. Lumin. 102-103, 445-450 (2003).
66. Bridot JL, Faure AC, Laurent S et al.: Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J. Am. Chem. Soc. 129, 5076-5084 (2007).
67. 3 oxide between fber single crystal and the nano-size powders. J. Crystal Growth 265, 459-465 (2004).
68. 3 luminescent powders by the polyol method. J. Solid State Chem. 178, 989-997 (2005).
69. 3 phosphor fne spherical powders using polyol-mediated synthesis. Appl. Phys. A: Mater. Sci. Process. A81, 1385-1391 (2005).
70. Louis C, Bazzi R, Marquette CA et al.: Nanosized hybrid particles with double luminescence for biological labelling. Chem. Mater. 17, 1673-1682 (2005).
71. Faure AC, Hoffmann C, Bazzi R et al.: Functionalization of luminescent aminated particles for facile bioconjugation. ACS Nano 2, 2273-2282 (2008).
72. Faure AC, Dufort S, Josserand V et al.: Control of the in vivo biodistribution of hybrid nanoparticles with different poly(ethylene glycol) coatings. Small 5, 2565-2575 (2009).
73. Louis C, Roux S, Ledoux G et al.: Luminescence enhancement by energy transfer in core-shell structures. Chem. Phys. Lett. 429, 157-160 (2006).
74. Louis C, Roux S, Ledoux G et al.: Gold nano-antennas for increasing luminescence. Adv. Mater. 16, 2163-2166 (2004).
75. Martini M, Perriat P, Montagna M et al.: How gold particles suppress concentration quenching of fuorophores encapsulated in silica beads. J. Phys. Chem. C 113, 17669-17677 (2009).
76. Barbillon G, Faure AC, El Kork N et al.: How nanoparticles encapsulating fuorophores allow a double detection of biomolecules by localized surface plasmon resonance and luminescence. Nanotechnology 19, 035705 (2008).
77. Coderre JA, Button TM, Micca PL, Fisher CD, Nawrocky MM, Liu HB: Neutron capture therapy of the 9L rat gliosarcoma using the P-boronphenylalanine- fructose complex. Int. J. Radiat. Oncol. Biol. Phys. 30, 643-652 (1994).
78. Sarin H, Kanevsky AS, Wu HT et al.: Physiologic upper limit of pore size in the blood tumor barrier of malignant solid tumors. J. Translational Med. 7, 51 (2009).
79. Fizet J, Rivière C, Bridot JL et al.: Multi-luminescent hybrid gadolinium oxide nanoparticles as potential cell labeling. J. Nanosci. Nanotech. 9, 1-9 (2009).
80. Bridot JL, Dayde D, Rivière C et al.: Hybrid gadolinium oxide nanoparticles combining imaging and therapy. J. Mater. Chem. 19, 2328-2335 (2009).
81. Sarin H, Kanevsky AS, Wu HT et al.: Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J. Translational Med. 6, 80 (2008).